| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aims and Scope/Editorial Board
|
|
|
|
143 |
C |
p. iii
|
artikel
|
| 2 |
A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab
|
Zhou, Yuling
|
|
|
143 |
C |
p. 55-59
|
artikel
|
| 3 |
A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226
|
Juergens, Rosalyn A.
|
|
|
143 |
C |
p. 1-11
|
artikel
|
| 4 |
Attenuated isolated 3’ signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC
|
Smuk, Gábor
|
|
|
143 |
C |
p. 80-85
|
artikel
|
| 5 |
Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors
|
Roch, Benoît
|
|
|
143 |
C |
p. 19-26
|
artikel
|
| 6 |
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients
|
Boysen Fynboe Ebert, Eva
|
|
|
143 |
C |
p. 67-72
|
artikel
|
| 7 |
C-Myc in mucinous colloid carcinoma of the lung
|
Handra-Luca, Adriana
|
|
|
143 |
C |
p. 93-94
|
artikel
|
| 8 |
Contents
|
|
|
|
143 |
C |
p. v-vi
|
artikel
|
| 9 |
Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)
|
Sherman, Shira
|
|
|
143 |
C |
p. 40-46
|
artikel
|
| 10 |
Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation
|
Okuno, Takae
|
|
|
143 |
C |
p. 95-96
|
artikel
|
| 11 |
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort
|
Sanchis-Borja, Mateo
|
|
|
143 |
C |
p. 36-39
|
artikel
|
| 12 |
Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy
|
Veronesi, Giulia
|
|
|
143 |
C |
p. 73-79
|
artikel
|
| 13 |
Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer
|
Sheinson, Daniel
|
|
|
143 |
C |
p. 86-92
|
artikel
|
| 14 |
Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer
|
Karayama, Masato
|
|
|
143 |
C |
p. 47-54
|
artikel
|
| 15 |
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
|
Eide, Inger Johanne Zwicky
|
|
|
143 |
C |
p. 27-35
|
artikel
|
| 16 |
Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas
|
Trejo Bittar, Humberto E.
|
|
|
143 |
C |
p. 12-18
|
artikel
|
| 17 |
Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma
|
Kneuertz, Peter J.
|
|
|
143 |
C |
p. 60-66
|
artikel
|
| 18 |
SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer
|
Ma, Li
|
|
|
143 |
C |
p. 97-100
|
artikel
|
Tijdschrift beschrijving